Recent Updates
Recently added Catalysts
BMY Neutral Sentiment

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

Key Takeaway: Bristol Myers Squibb is scheduled to report its financial results for the second quarter of 2026 on July 30, 2026. This announcement is part of the company's regular financial reporting cycle. Investors and analysts will be looking for insights into the company's performance during this period.
Price reaction · baseline $55.28 (2026-06-17 close) · hit pre-market · clean, no other BMY news in the window
day 0 close · peak
-2.3%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+20%
120-day peak, hindsight
Typical move
1.7%
average across 15 past catalysts
Lead asset
Muraglitazar
Phase 3 · Type 2 Diabetes

Full Press Release Details

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2026 on Thursday, July 30, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:15 a.m. ET.
Investors and the general public are invited to listen to a live audio webcast of the call athttp://investor.bms.com. Materials related to the call will be available on the company’sInvestor Relations websiteprior to the start of the conference call.
A replay of the webcast will be availablehereapproximately three hours after the conference call concludes.
About Bristol Myers Squibb: Transforming Patients’ Lives Through ScienceAt Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us atBMS.comand follow us onLinkedIn,X,YouTube,FacebookandInstagram.
corporatefinancial-news
Last updated: Jun 18, 2026